Stemline Therapeutics Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Stemline Therapeutics Inc |
Stock Symbol : | NASDAQ: STM |
Class Period Start: | 01/19/2017 |
Class Period End: | 02/01/2017 |
Lead Plaintiff motion: | 04/04/2017 |
Date Filed: | 02/03/2017 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of New York |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the April 4, 2017 lead plaintiff deadline in a class action lawsuit filed against Stemline Therapeutics Inc (NASDAQ: STM) (“Stemline” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Stemline Therapeutics Inc securities between January 19, 2017 and February 1, 2017, have until April 4, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Stemline Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. On February 2, 2017, Bloomberg revealed that a patient in a clinical trial of Stemline's cancer drug SL-401 died from a side effect. Making this is the third death linked to SL-401 toxicity. Once this information was released to the public, NASDAQ: STM fell significantly, causing investors harm. If you were negatively impacted by your investment in Stemline Therapeutics Inc securities between January 19, 2017 and February 1, 2017 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |